The DOI matches its Crossref record; 83 of the 83 references it cites were found in a registry or an index.
Optimizing anti-TNF treatment in inflammatory bowel disease
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
Self-citationTuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent
Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., & Braun, M. M. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011110 · Cited by 3,710
Targan, S. R., Hanauer, S. B., van Deventer, S. J. H., Mayer, L., Present, D. H., Braakman, T., DeWoody, K. L., Schaible, T. F., & Rutgeerts, P. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710093371502 · Cited by 3,135
Self-citationInfliximab for the Treatment of Fistulas in Patients with Crohn's Disease
Present, D. H., Rutgeerts, P., Targan, S., Hanauer, S. B., Mayer, L., van Hogezand, R. A., Podolsky, D. K., Sands, B. E., Braakman, T., DeWoody, K. L., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199905063401804 · Cited by 2,752
Self-citationInfliximab Maintenance Therapy for Fistulizing Crohn's Disease
Sands, B. E., Anderson, F. H., Bernstein, C. N., Chey, W. Y., Feagan, B. G., Fedorak, R. N., Kamm, M. A., Korzenik, J. R., Lashner, B. A., Onken, J. E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa030815 · Cited by 2,226
Self-citationInfluence of Immunogenicity on the Long-Term Efficacy of Infliximab in Crohn's Disease
Baert, F., Noman, M., Vermeire, S., Van Assche, G., D' Haens, G., Carbonez, A., & Rutgeerts, P. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020888 · Cited by 2,015
Self-citationElliott, M. J., Maini, R. N., Feldmann, M., Kalden, J. R., Antoni, C., Smolen, J. S., Leeb, B., Breedveld, F. C., Macfarlane, J. D., Bijl, J. A., et al. (1994) · The Lancet · doi:10.1016/s0140-6736(94)90628-9 · Cited by 1,682
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Braun, J., Brandt, J., Listing, J., Zink, A., Alten, R., Golder, W., Gromnica-lhle, E., Kellner, H., Krause, A., Schneider, M., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08215-6 · Cited by 1,261
Sampaio, E. P., Sarno, E. N., Galilly, R., Cohn, Z. A., & Kaplan, G. (1991) · The Journal of experimental medicine · doi:10.1084/jem.173.3.699 · Cited by 1,192
Faubion, W. A., Loftus, E. V., Harmsen, W. S., Zinsmeister, A. R., & Sandborn, W. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.26279 · Cited by 1,144
Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
van Dullemen, H. M., van Deventer, S. J. H., Hommes, D. W., Bijl, H. A., Jansen, J., Tytgat, G. N. J., & Woody, J. (1995) · Gastroenterology · doi:10.1016/0016-5085(95)90277-5 · Cited by 1,084
Rutgeerts, P., D'Haens, G., Targan, S., Vasiliauskas, E., Hanauer, S. B., Present, D. H., Mayer, L., Van Hogezand, R. A., Braakman, T., DeWoody, K. L., et al. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70332-x · Cited by 1,080
Self-citationTreatment of Crohn's Disease with 6-Mercaptopurine: A Long-Term, Randomized, Double-Blind Study
Present, D. H., Korelitz, B. I., Wisch, N., Glass, J. L., Sachar, D. B., & Pasternack, B. S. (1980) · New England Journal of Medicine · doi:10.1056/nejm198005013021801 · Cited by 1,042
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease
Rutgeerts, P., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.11.014 · Cited by 943
Self-citationMethotrexate for the Treatment of Crohn's Disease
Feagan, B. G., Rochon, J., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Gillies, R., Hopkins, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199502023320503 · Cited by 911
Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial
Sandborn, W. J., Hanauer, S. B., Katz, S., Safdi, M., Wolf, D. G., Baerg, R. D., Tremaine, W. J., Johnson, T., Diehl, N. N., & Zinsmeister, A. R. (2001) · Gastroenterology · doi:10.1053/gast.2001.28674 · Cited by 910
Colombel, J.-F., Loftus, E. V., Tremaine, W. J., Egan, L. J., Harmsen, W. S., Schleck, C. D., Zinsmeister, A. R., & Sandborn, W. J. (2004) · Gastroenterology · doi:10.1053/j.gastro.2003.10.047 · Cited by 899
REINECKER, H.-C., STEFFEN, M., WITTHOEFT, T., PFLUEGER, I., SCHREIBER, S., MacDERMOTT, R. P., & RAEDLER, A. (2008) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.1993.tb05997.x · Cited by 856
Natalizumab for Active Crohn's Disease
Ghosh, S., Goldin, E., Gordon, F. H., Malchow, H. A., Rask-Madsen, J., Rutgeerts, P., Vyhnálek, P., Zádorová, Z., Palmer, T., & Donoghue, S. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa020732 · Cited by 808
Self-citationD'Haens, G., Van Deventer, S., Van Hogezand, R., Chalmers, D., Kothe, C., Baert, F., Braakman, T., Schaible, T., Geboes, K., & Rutgeerts, P. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70005-3 · Cited by 745
Self-citationA Comparison of Methotrexate with Placebo for the Maintenance of Remission in Crohn's Disease
Feagan, B. G., Fedorak, R. N., Irvine, E. J., Wild, G., Sutherland, L., Steinhart, A. H., Greenberg, G. R., Koval, J., Wong, C. J., Hopkins, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006013422202 · Cited by 727
Van den Brande, J. M. H., Braat, H., van den Brink, G. R., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 723
Treatment of Ankylosing Spondylitis by Inhibition of Tumor Necrosis Factor α
Gorman, J. D., Sack, K. E., & Davis, J. C. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012664 · Cited by 704
Frequency of glucocorticoid resistance and dependency in Crohn's disease.
Munkholm, P., Langholz, E., Davidsen, M., & Binder, V (1994) · Gut · doi:10.1136/gut.35.3.360 · Cited by 654
Lügering, A., Schmidt, M., Lügering, N., Pauels, H.-G., Domschke, W., & Kucharzik, T. (2001) · Gastroenterology · doi:10.1053/gast.2001.28702 · Cited by 588
A controlled double blind study of azathioprine in the management of Crohn's disease.
Candy, S., Wright, J., Gerber, M., Adams, G., Gerig, M., & Goodman, R. (1995) · Gut · doi:10.1136/gut.37.5.674 · Cited by 567
Breese, E. J., Michie, C. A., Nicholls, S. W., Murch, S. H., Williams, C. B., Domizio, P., Walker-Smith, J. A., & Macdonald, T. T. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90398-0 · Cited by 566
Farrell, R. J., Alsahli, M., Jeen, Y.-T., Falchuk, K. R., Peppercorn, M. A., & Michetti, P. (2003) · Gastroenterology · doi:10.1053/gast.2003.50145 · Cited by 550
Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease
ten Hove, T. (2002) · Gut · doi:10.1136/gut.50.2.206 · Cited by 545
Disease Activity Courses in a Regional Cohort of Crohn's Disease Patients
Munkholm, P., Langholz, E., Davidsen, M., & Binder, V. (1995) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529509096316 · Cited by 501
TREATMENT OF ANKYLOSING SPONDYLITIS BY INHIBITION OF TUMOR NECROSIS FACTOR a
Orman, D., Enneth, K., Ack, E. S., Ohn, J., & Avis, C. D. (2002) · Cited by 470
Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine
Bouhnik, Y., Scemama, G., Taï, R., Matuchansky, C., Rambaud, J.-C., Lémann, M., Modigliani, R., & Mary, J.-Y. (1996) · The Lancet · doi:10.1016/s0140-6736(96)90402-x · Cited by 466
Baert, F. J., D'Haens, G. R., Peeters, M., Hiele, M. I., Schaible, T. F., Shealy, D., Geboes, K., & Rutgeerts, P. J. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70224-6 · Cited by 462
Self-citationMagnetic resonance imaging of the effects of infliximab on perianal fistulizing Crohn's disease
Van Assche, G. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)05909-9 · Cited by 457
Self-citationInfliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study
Sands, B. E., Tremaine, W. J., Sandborn, W. J., Rutgeerts, P. J., Hanauer, S. B., Mayer, L., Targan, S. R., & Podolsky, D. K. (2001) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200105000-00001 · Cited by 422
Self-citationHommes, D., Van Den Blink, B., Plasse, T., Bartelsman, J., Xu, C., Macpherson, B., Tytgat, G., Peppelenbosch, M., & Van Deventer, S. (2002) · Gastroenterology · doi:10.1053/gast.2002.30770 · Cited by 378
Probert, C. S. J., Hearing, S. D., Schreiber, S., Kühbacher, T., Ghosh, S., Arnott, I. D. R., & Forbes, A. (2003) · Gut · doi:10.1136/gut.52.7.998 · Cited by 355
Van den Bosch, F., Kruithof, E., Baeten, D., Herssens, A., de Keyser, F., Mielants, H., & Veys, E. M. (2002) · Arthritis & Rheumatism · doi:10.1002/art.511 · Cited by 352
Vermeire, S., Noman, M., Van Assche, G., Baert, F., Van Steen, K., Esters, N., Joossens, S., Bossuyt, X., & Rutgeerts, P. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00701-7 · Cited by 327
Self-citationThalidomide therapy for patients with refractory Crohn's disease: An open-label trial
Ehrenpreis, E. D., Kane, S. V., Cohen, L. B., Cohen, R. D., & Hanauer, S. B. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70276-3 · Cited by 326
Tumour-necrosis-factor antibody treatment in Crohn's disease
Derkx, B., Taminiau, J., Radema, S., Stronkhorst, A., Wortel, C., Tytgat, G., & van Deventer, S. (1993) · The Lancet · doi:10.1016/0140-6736(93)91375-v · Cited by 308
Etanercept therapy in children with treatment-resistant uveitis
Reiff, A., Takei, S., Sadeghi, S., Stout, A., Shaham, B., Bernstein, B., Gallagher, K., & Stout, T. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200106)44:6<1411::aid-art235>3.0.co;2-o · Cited by 298
Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients
Ricart, E., Panaccione, R., Loftus, E. V., Tremaine, W. J., & Sandborn, W. J. (2001) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2001.03612.x · Cited by 285
Vasiliauskas, E. A., Kam, L. Y., Abreu-Martin, M. T., Hassard, P. V., Papadakis, K. A., Yang, H., Zeldis, J. B., & Targan, S. R. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70277-5 · Cited by 281
Louis, E. J., Vermeire, S. A. R. A., Rutgeerts, P., Vos, M. D., Gossum, A. V., Pescatore, P., Fiasse, R., Pelckmans, P. A., Reynaert, H., D’Haens, G., et al. (2002) · Scandinavian Journal of Gastroenterology · doi:10.1080/713786515 · Cited by 270
Self-citationSandborn, W. J., Feagan, B. G., Hanauer, S. B., Present, D. H., Sutherland, L. R., Kamm, M. A., Wolf, D. C., Baker, J. P., Hawkey, C., Archambault, A., et al. (2001) · Gastroenterology · doi:10.1053/gast.2001.24042 · Cited by 257
Predictors of response to infliximab in patients with Crohn's disease
Parsi, M. A., Achkar, J., Richardson, S., Katz, J., Hammel, J. P., Lashner, B. A., & Brzezinski, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.35390 · Cited by 252
Topstad, D. R., Panaccione, R., Heine, J. A., Johnson, D. R. E., MacLean, A. R., & Buie, D. W. (2003) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-6611-4 · Cited by 244
Vermeire, S. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04348-4 · Cited by 229
Self-citationTaylor, K. D., Yang, H., Landers, C. J., Rotter, J. I., Targan, S. R., Plevy, S. E., & Barry, M. J. (2001) · Gastroenterology · doi:10.1053/gast.2001.23966 · Cited by 222
Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease
Regueiro, M. (2003) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(03)00430-1 · Cited by 221
Van den Bosch, F., Kruithof, E., Vos, M. D., Keyser, F. D., & Mielants, H. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03239-6 · Cited by 220
Löfberg, R., Rutgeerts, P., Malchow, H., Lamers, C., Danielsson, A., Olaison, G., Jewell, D., Ostergaard Thomsen, O., Lorenz-Meyer, H., Goebell, H., et al. (1996) · Gut · doi:10.1136/gut.39.1.82 · Cited by 209
Self-citationNOD2/CARD15 does not influence response to infliximab in Crohn's disease
Vermeire, S., Louis, E., Rutgeerts, P., De Vos, M., Van Gossum, A., Belaiche, J., Pescatore, P., Fiasse, R., Pelckmans, P., Vlietinck, R., et al. (2002) · Gastroenterology · doi:10.1053/gast.2002.34172 · Cited by 208
Self-citationCornillie, F., Shealy, D., D'Haens, G., Geboes, K., Van Assche, G., Ceuppens, J., Wagner, C., Schaible, T., Plevy, S. E., Targan, S. R., et al. (2001) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2001.00956.x · Cited by 202
Self-citationAnnual cost of care for Crohn's disease: a payor perspective
Feagan, B. (2000) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(00)01053-4 · Cited by 193
Therapeutic Approaches in Multiple Sclerosis: Lessons from Failed and Interrupted Treatment Trials
Wiendl, H., & Hohlfeld, R. (2002) · BioDrugs · doi:10.2165/00063030-200216030-00003 · Cited by 183
Efficacy of anti-tumor necrosis factor therapy in patients with ulcerative colitis
Su, C. (2002) · The American Journal of Gastroenterology · doi:10.1016/s0002-9270(02)04384-8 · Cited by 175
El-Shabrawi, Y., & Hermann, J. (2002) · Ophthalmology · doi:10.1016/s0161-6420(02)01292-7 · Cited by 164
Inflammatory Bowel Diseases: Health Care and Costs in Sweden in 1994
Blomqvist, P., & Ekbom, A. (1997) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529709002993 · Cited by 160
Bell, S., Halligan, S., Windsor, A. C. J., et al. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01427.x · Cited by 158
The Cost of Hospitalization in Crohn's Disease
Cohen, R. D., Larson, L. R., Roth, J., Becker, R. V., & Mummert, L. H. (2000) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2000.01779.x · Cited by 147
Mascheretti, S., Hampe, J., Croucher, P. J. P., Nikolaus, S., Andus, T., Schubert, S., Olson, A. D., Bao, W., Fölsch, U. R., & Schreiber, S. (2002) · Pharmacogenetics · doi:10.1097/00008571-200210000-00002 · Cited by 147
van Bodegraven, A. A., Sloots, C. E. J., Felt-Bersma, R. J. F., et al. (2002) · Diseases of the Colon & Rectum · doi:10.1007/s10350-004-6111-6 · Cited by 146
Response to infliximab is related to disease duration in paediatric Crohn's disease
Lionetti, P., Bronzini, F., Salvestrini, C., Bascietto, C., Canani, R. B., Angelis, G. L. D., Guariso, G., Martelossi, S., Papadatou, B., & Barabino, A. V. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01672.x · Cited by 144
Mascheretti, S., Hampe, J., Kühbacher, T., Herfarth, H. H., Krawczak, M., Fölsch, U. R., & Schreiber, S. (2002) · The Pharmacogenomics Journal · doi:10.1038/sj.tpj.6500091 · Cited by 142
Esters, N., Vermeire, S., Joossens, S. B. A., Noman, M., Louis, E., Bélaïche, J., Vos, M. D., Gossum, A. M. V., Pescatore, P., Fiasse, R., et al. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.05689.x · Cited by 142
Self-citationBauditz, J., Wedel, S., & Lochs, H. (2002) · Gut · doi:10.1136/gut.50.2.196 · Cited by 132
Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea.
Nicholls, S. J., Stephens, S., Braegger, C., Walker‐Smith, J. A., & MacDonald, T. T. (1993) · Journal of Clinical Pathology · doi:10.1136/jcp.46.8.757 · Cited by 119
Infliximab Decreases Resource Use Among Patients With Crohn's Disease
Rubenstein, J. H., Chong, R. Y., & Cohen, R. D. (2002) · Journal of Clinical Gastroenterology · doi:10.1097/00004836-200208000-00007 · Cited by 118
Gornet, J., Couve, S., Hassani, Z., Delchier, J. C., Marteau, P. R., Cosnes, J., Bouhnik, Y., Dupas, J. L., Modigliani, R., Taillard, F., et al. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01686.x · Cited by 104
Rutgeerts, P., Lemmens, L., Assche, G. V., Noman, M., Borghini-Fuhrer, I., & Goedkoop, R. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01414.x · Cited by 98
Self-citationSabaté, J., Villarejo, J., Lémann, M., Bonnet, J., Allez, M., & Modigliani, R. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01273.x · Cited by 71
Infliximab Treatment for Crohn's Disease: One-Year Experience in a Dutch Academic Hospital
Hommes, D. W., van de Heisteeg, B., van der Spek, M., Bartelsman, J. F. W. M., & van Deventer, S. J. H. (2002) · Inflammatory Bowel Diseases · doi:10.1097/00054725-200203000-00002 · Cited by 62
Mortimore, M., Gibson, P. R., Selby, W. S., Radford‐Smith, G. L., Florin, T. H., & THE INFLIXIMAB USER GROUP (2001) · Internal Medicine Journal · doi:10.1046/j.1445-5994.2001.00039.x · Cited by 46
Maintenance infliximab for Crohn's disease
Hanauer, S. B. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11537-6 · Cited by 44
Schreiber, S., Rutgeerts, P. J., Fedorak, R. N., Khaliq-Kareemi, M., Kamm, M. A., & Patel, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)80301-3 · Cited by 36
Self-citationEffects of anti‐tumour necrosis factor‐α therapy on the quality of life in Crohn's disease
Balkom, B. P. J. V., Schoon, E. J., Stockbrügger, R. W., Wolters, F. J., van Hogezand, R. A., van Deventer, S. J. H., Oldenburg, B., van Dullemen, H. M., & Rüssel, M. G. (2002) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2002.01268.x · Cited by 33
Infliximab treatment for Crohn's disease
Conroy, C., & Cattell, R. (2001) · Postgraduate Medical Journal · doi:10.1136/pmj.77.909.436 · Cited by 26
Sandborn, W. J., Feagan, B., Radford‐Smith, G. L., Kovács, Á., Enns, R. A., & Patel, J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)80302-5 · Cited by 25
Verdachtsf�lle schwerwiegender Nebenwirkungen nach Infliximab (Remicade�) aus Deutschland
Andus, T., Stange, E. F., H�ffler, D., & Keller‐Stanislawski, B. (2003) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-003-1282-9 · Cited by 20
Infliximab use in Crohn’s disease
Bewtra, M., & Lichtenstein, G. R. (2005) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.5.4.589 · Cited by 13
Cited by
Dignass, A., Van Assche, G., Lindsay, J. O., Lémann, M., Söderholm, J., Colombel, J. F., Danese, S., D'Hoore, A., Gassull, M., Gomollón, F., et al. (2010) · Journal of Crohn's and Colitis · doi:10.1016/j.crohns.2009.12.002 · Cited by 1,498
Self-citationGuidelines for the management of inflammatory bowel disease in adults
Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., Driscoll, R., Mitton, S., Orchard, T., Rutter, M., Younge, L., et al. (2011) · Gut · doi:10.1136/gut.2010.224154 · Cited by 1,419
Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis
Smillie, C. S., Biton, M., Ordovas-Montanes, J., Sullivan, K. M., Burgin, G., Graham, D. B., Herbst, R. H., Rogel, N., Slyper, M., Waldman, J., et al. (2019) · Cell · doi:10.1016/j.cell.2019.06.029 · Cited by 1,394
Management of Crohn's Disease in Adults
Lichtenstein, G. R., Hanauer, S. B., & Sandborn, W. J. (2009) · The American Journal of Gastroenterology · doi:10.1038/ajg.2008.168 · Cited by 1,173
Guidelines for the management of inflammatory bowel disease in adults
Carter, M. J., Lobo, A. J., & Travis, S. P. L. (2004) · Gut · doi:10.1136/gut.2004.043372 · Cited by 1,083
Metadata
- Authors
- Rutgeerts, P., van Assche, G., & Vermeire, S.
- Venue
- Gastroenterology
- Publisher
- Elsevier BV
- Published
- 2004-05
- Volume
- 126
- Issue
- 6
- Pages
- 1593-1610
- ISSN
- 0016-5085 (ISSN-L)
- OpenAlex
- W2135423184
- Cited by
- 429
- References
- 83
- FWCI
- 24.58
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.